Aerovate Therapeutics Inc... (AVTE)
NASDAQ: AVTE
· Real-Time Price · USD
2.68
0.00 (0.00%)
At close: Apr 28, 2025, 3:59 PM
Company Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Timothy P. Noyes |
Contact Details
Address: 930 Winter Street Waltham, Massachusetts United States | |
| Website | https://aerovatetx.com |
Stock Details
| Ticker Symbol | AVTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001798749 |
| CUSIP Number | 008064107 |
| ISIN Number | US0080641071 |
| Employer ID | 83-1377888 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy P. Noyes M.B.A. | Chief Executive Officer & Director |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer & Secretary |
| George A. Eldridge | Chief Financial Officer & Treasurer |
| Donna Dea | Head of Regulatory Affairs |
| Dr. Cheryl Lassen BSc., M.D., MBBCh | Senior Vice President of Clinical Development |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
| Dr. Sanjeev Khindri | Executive Vice President of Clinical Development |
| Hunter Gillies M.D. | Chief Medical Officer |
| Stephen K. Yu | Senior Vice President of Quality |
| Susan Fischer | Executive Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 13, 2025 | 8-A12B/A | [Amend] Filing |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 17, 2025 | SCHEDULE 13G | Filing |
| Jul 14, 2025 | 4 | Filing |
| Jul 14, 2025 | 3 | Filing |
| Jul 01, 2025 | 8-K | Current Report |
| Jun 30, 2025 | S-8 | Filing |